Drugs Made In America Acquisition Corp. Ordinary Shares
DMAA scores 5.2 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -35.3 points significantly impact the ranking. Without these adjustments, DMAA would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| DMAA | 5.2 | 42.0 | 0.0% | 0.0% | $350M |
| CME | 86.4 | 27.2 | 9.9% | 57.5% | $114.0B |
| FHB | 84.9 | 11.8 | 3.2% | 24.2% | $3.1B |
| ACT | 84.5 | 8.9 | 2.4% | 54.6% | $6.1B |
| CINF | 84.2 | 10.7 | 11.4% | 18.9% | $25.4B |
| SEIC | 82.2 | 14.0 | 10.7% | 27.3% | $9.9B |
| TROW | 79.9 | 10.1 | 3.1% | 28.5% | $20.5B |
| QQQX | 79.7 | 10.4 | 48.6% | 257.3% | $1.4B |
| IBOC | 78.2 | 10.6 | 7.5% | 40.1% | $4.2B |
| HWC | 77.8 | 12.2 | -1.5% | 24.1% | $5.6B |
| FFIN | 77.5 | 18.8 | 11.7% | 30.7% | $4.7B |
| TRMK | 77.1 | 11.9 | 34.8% | 19.3% | $2.6B |
| NMIH | 77.1 | 7.7 | 8.4% | 55.1% | $3.0B |
| EWBC | 76.7 | 12.7 | 4.6% | 28.3% | $15.3B |
| WSFS | 76.3 | 12.8 | -3.1% | 21.1% | $3.5B |
| MCHB | 76.1 | N/A | 123.7% | 23.2% | $3.1B |
| Sector Average | 47.5 | 26.8 | 13.4% | -2.8% | â |
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Stock is losing momentum near highs. The 200-day SMA is flattening or beginning to turn. Historically, this stage precedes distribution.
Stage 3 distribution â institutional selling pressure is building. Avoid new positions. If already holding, consider reducing and tightening stops below SMA50.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Income | $-263,703 | $-131,919 | $-330,925 | $-279 |
| Net Income | $2M | $2M | $1M | $-279 |
| EPS (Diluted) | $0.07 | $0.07 | $49.18 | $-0.03 |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A |
This stock has limited trading volume and/or float. Institutional investors may face difficulty entering or exiting positions without significant price impact. A post-hoc penalty has been applied to the composite score (this is not a backtested model factor â it is a practical tradability overlay).
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.